Before accessing this site, you agree that you have read and agree to the disclaimers at the bottom of this page.
Last Price: 16.1 - Change: 0.47 - Change %: 3.007
Industry: Health Information ServicesFollow @stockchartsai on Twitter
In the past 30 trading days, CERT has been trading in a range between $14.97 and $12.12 (gray range band). Red lines on the chart represent key resistance levels and Green lines represent key support levels. As the price moves above the lines you will notice they turn green and red if price moves below a line.
CERT is trading between resistance at $16.67 about 4% to the upside and support at $14.38 -11% to the downside. If it can break above the resistance, it could have some more upside to the next line of resistance at $19.16, about a 19% move. If the price starts to turn down and fails to get through this level or enters a yellow zone, we would consider profit taking or exiting the position. If it enters a red zone on the chart we would exit the position.
Certara Inc (CERT) entered a Green zone 17 days ago on the AI powered stock chart. Wall Street analysts have a recent rating of 3.750, which is a Buy. The current analyst target price is $18.57, which gives it a potential upside of 15.34 % from the recent price of 16.10. The stock is trading 55.03% (potential upside) below its 52 week high of $24.96 and 36.33 % (potential downside) above its 52 week low of $11.81 - based on the recent price.
Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.
|Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
Certara's Simcyp™ Biopharmaceutics software helps biopharmaceutic, formulation & CMC scientists formulate complex new and generic drugs faster and cheaper.
Tue, 21 Nov 2023 16:30:00 -0500
|Certara Inc. (CERT) Q3 2023 Earnings Call Transcript
Certara Inc. (NASDAQ:CERT ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens Inc David Windley - Jefferies Mike Ryskin - Bank of America Max Smock - William Blair Joe Vruwink - Baird Vikram Purohit - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Certara Third Quarter 2023 Earnings Conference Call.
Source: Seeking Alpha
Wed, 08 Nov 2023 22:41:08 -0500
|Certara, Inc. (CERT) Q3 Earnings Meet Estimates
Certara, Inc. (CERT) came out with quarterly earnings of $0.11 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.10 per share a year ago.
Source: Zacks Investment Research
Wed, 08 Nov 2023 20:17:04 -0500
|Certara Reports Third Quarter 2023 Financial Results
PRINCETON, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023.
Wed, 08 Nov 2023 16:10:00 -0500
|Circling Back On Certara
Certara, Inc. provides biosimulation software and services to the biotech and biopharma industry. The company is enjoying sales growth from its software division in the mid-teen but service growth is lagging. Analysts have mixed opinions on Certara's prospects even as the company is expanding its AI capabilities. An updated analysis is provided in the paragraphs below.
Source: Seeking Alpha
Tue, 17 Oct 2023 14:36:21 -0400
Stock Analyzed Each Night
Easily Upload Track Your Stocks
See Lists of Stocks Starting New Trends
The information contained on this website is solely for educational purposes, and does not constitute investment advice. The risk of trading in securities markets can be substantial. By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site. Stocks, Futures and options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the stock, futures and options markets. Don't trade with money you can't afford to lose. This website is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this website. The past performance of any trading system or methodology is not necessarily indicative of future results. Individual results may vary, and testimonials are not claimed to represent typical results. All testimonials are by real people, and may not reflect the typical purchaser’s experience, and are not intended to represent or guarantee that anyone will achieve the same or similar results. HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY, SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.